VANCOUVER, March 7, 2017 /CNW/ - RepliCel Life
Sciences Inc. (OTCQB:REPCF) (TSXV:RP) (FRA:P6P2) ("RepliCel" or
the "Company"), a clinical stage regenerative medicine company
developing unique biologic products for pattern baldness and
thinning hair, aging and sun-damaged skin, and chronic tendon
degeneration, today announced the company has retained The FreeMind
Group ("FreeMind"), a premier international firm that assists life
science organizations in securing non-dilutive funding from
granting agencies and private foundations. RepliCel aims to secure
non-dilutive capital to support research, clinical development,
and/or manufacturing priorities to accelerate value creation and
the commercialization of its products.
"We have a number of strategic clinical and non-clinical
projects which are ideally positioned for external collaborations
and non-dilutive funding. These include basic research,
manufacturing optimization, product development, and clinical
objectives which have the potential to create significant
intellectual property and shareholder value," stated RepliCel
President and CEO, R. Lee
Buckler. "FreeMind has a proven track record and
commitment to success-based remuneration that convinces us they
will bring significant value to our programs. I look forward to
updating our shareholders over the coming months with their
progress."
About The FreeMind Group
Established in 1999, The
FreeMind Group is the largest consulting group of its kind working
with academics and industry alike. Their goal is to assist in
maximizing potential to receive funding from non-dilutive sources.
They have experience in seeking funding from nearly all NIH
Institutes, Department of Defense, NSF, FDA, BARDA, etc., as well
as private foundations. FreeMind's team is dedicated to guiding
non-dilutive funding efforts from identification of the most
suitable opportunity, through to submission and subsequent award.
Their expertise in applying for grants and contracts extends
throughout every government mechanism, as well as private
foundations open to funding the life sciences. FreeMind's proven
long-term approach has garnered over $1.5
billion to date; awards range from $150,000 to $150 million per client project. For
more information, visit http://www.freemindconsultants.com.
About RepliCel Life Sciences
RepliCel is a
regenerative medicine company focused on developing autologous cell
therapies that address conditions caused by a deficit of healthy
cells required for normal tissue healing and function. The
Company's product pipeline is comprised of two ongoing clinical
trials (RCT-01 for tendon repair and RCS-01 for skin rejuvenation)
as well as its RCH-01 hair restoration product under exclusive
license by Shiseido Company for certain Asian countries. All
product candidates are based on RepliCel's innovative technology,
utilizing cell populations isolated from a patient's healthy hair
follicles. RepliCel has also developed a proprietary injection
device (RCI-02) optimized for the administration of its products
and licensable for use with other dermatology applications. Please
visit http://replicel.com/ for additional information.
Forward-Looking Statements
This and related press
release contain forward-looking statements and information that
involve various risks and uncertainties regarding future
events. Although the Company believes that the expectations
reflected in the forward-looking statements are reasonable, it
cannot guarantee future results, levels of activity or performance.
Further, any forward-looking statement speaks only as of the date
on which such statement is made and, except as required by
applicable law, the Company undertakes no obligation to update any
forward-looking statement to reflect events or circumstances after
the date on which such statement is made or to reflect the
occurrence of unanticipated events. New factors emerge from time to
time, and it is not possible for management to predict all of such
factors and to assess in advance the impact of such factors on the
Company's business or the extent to which any factor, or
combination of factors, may cause actual results to differ
materially from those contained in any forward-looking statement.
Readers should consult all of the information set forth herein and
should also refer to the risk factor disclosure outlined in the
Company's annual report on Form 20-F for the fiscal year ended
December 31, 2015 and other periodic
reports filed from time-to-time with the Securities and Exchange
Commission on Edgar at www.sec.gov and with the
British Columbia Securities Commission on SEDAR
at www.sedar.com.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
SOURCE RepliCel Life Sciences Inc.